Insugen-R 100IU/ml Refil contains human insulin at a concentration of 100 international units per milliliter, formulated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin analog is indicated for the control of hyperglycemia in patients with type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents are insufficient to achieve adequate glycemic control. Insugen-R mimics endogenous insulin by facilitating cellular glucose uptake, primarily in muscle and adipose tissue, and inhibiting hepatic glucose production, thereby lowering blood glucose levels. It is administered subcutaneously, typically 30 minutes before meals, to manage postprandial glucose excursions. Dosage and administration should be individualized based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goals. Caution is advised to avoid hypoglycemia, which may result from excessive insulin dosing, delayed meals, or increased physical activity. Patients should be educated on recognizing and managing hypoglycemic episodes. Insugen-R should be stored under recommended conditions to maintain potency. It is contraindicated in patients with hypersensitivity to human insulin or its excipients. Regular monitoring of blood glucose and periodic assessment of HbA1c levels are essential to optimize therapy and minimize complications associated with diabetes.